Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Onset 1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 29 Sep 2017 According to a Novo Nordisk media release, the US FDA has approved Fiasp for glycemic control in adults with tyep1 and type 2 diabetes based on data from this and other three trials (226655, 232775, 238002 trials from ONSET programme).
    • 15 Sep 2017 Results of post hoc analysis assessing the extent to which 1,5-anhydroglucitol levels reflect postprandial glucose control depending on HbA 1c responder status presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results assessing long term safety and efficacy of insulin aspart presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top